Glenmark Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha’s son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. By 2011 the founder of the company was one of the richest men in India,[2] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year’s sales; the growth was driven by Glenmark’s entry into the US and European generics markets , In the mid-2010s the generics industry in general began transitioning to the end of an era of giant patent cliffs in the pharmaceutical industry; patented drugs with sales of around $28 billion were set to come off patent in 2018, but in 2019 only about $10 billion in revenue was set to open for competition, and less Glenn Saldanha took the company down the path of seeking innovation, which was controversial within the company and with shareholders.[4] The company focused on new drugs[5] and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies.[4][6] In 2016 it had four such drugs in clinical trials.[7] For the financial year 2016–2017 its sales were around 81 billion INR (ca. $1.25 billion), making it the fourth-biggest Indian pharmaceutical companythe next year. Companies in the industry responded with consolidation or trying to generate new, patented drugs.
Script Name –GLENMARK
Expire Date-AUGUST
Buy Price –606
Profit Target-620/627
Stop Loss-600
Call Duration-CARRY FORWARD
Disclaimer : Trading in the stock market, currency, or commodity markets is risky and has the potential to lose money. –Atal Trade Effort calls you after analyzing all aspects of all stocks. Investing is a personal matter. However, only one. The risk of loss in trading and investment in Securities markets including Equities, Derivatives, commodities, and Currency can be substantial. All products that carry a substantial risk of loss up to your invested capital. It May not be suitable for everyone. You should therefore carefully consider whether such trading is suitable for you in light of your financial condition. You invest a portion of your total money that will not be affected by the loss. Never put all your money into trading and never borrow money for the business
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
Leave a Reply